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ABSTRACT 20 
Compound libraries that are screened for biological activity commonly contain heterocycles. Besides 21 
potency, drug-like properties need to be evaluated to ensure in vivo efficacy of test compounds. In this 22 
context, we determined hepatic and intestinal disposition profiles for 19 heterocyclic compounds. 23 
All studied compounds showed rapid uptake in suspended rat hepatocytes, whereas metabolism was 24 
poor and the rate-limiting step in hepatic elimination. In vitro assays demonstrated a relatively low 25 
solubility and high intestinal permeability. Based on these in vitro data, heterocycles were categorized 26 
in the biopharmaceutics classification system (BCS) and the biopharmaceutics drug disposition 27 
classification system (BDDCS) to predict disposition characteristics before clinical data are available. 28 
Our findings emphasized the importance to use hepatocytes in addition to microsomes to study 29 
metabolism, since the latter lack non-microsomal enzymes and cellular context. Moreover, 30 
intracellular exposure should be considered to gain insight in the relevant fraction of the compound 31 
available at the enzymatic site. Finally, the study reveals discrepancies associated with the 32 
classification of heterocycles in BCS versus BDDCS. These probably originate from the binary character 33 
of both systems. 34 
KEY WORDS: heterocycles, hepatic drug disposition, intestinal drug disposition, ADMET, 35 
biopharmaceutics drug disposition classification system (BDDCS)  36 
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ABBREVIATIONS: ABT, 1-aminobenzotriazole; ADMET, absorption distribution metabolism excretion 37 
toxicity; BCS, biopharmaceutics classification system; BDDCS, biopharmaceutics drug disposition 38 
classification system; Clint,basolateral, intrinsic basolateral clearance; Clint,canalicular, intrinsic canalicular 39 
clearance; Clint,met,hep, intrinsic metabolic clearance determined in hepatocytes; Clint,met,mic, intrinsic 40 
metabolic clearance determined in microsomes; Clint,uptake, intrinsic uptake clearance; Clpassive, passive 41 
uptake hepatocytes; Clrenal,filtration renal clearance through glomerular filtration; CYP, cytochrome P450; 42 
DMEM, Dulbecco’s modified Eagle’s medium; DMSO, dimethyl sulfoxide; ER, extraction ratio; FaSSIF, 43 
fasted state simulated intestinal fluid; FBS, fetal bovine serum; fu, unbound fraction; fu,hep, unbound 44 
fraction in hepatocyte incubations; fu,mic, unbound fraction in microsomal incubations; GFR glomerular 45 
filtration rat; HBa, hydrogen bond acceptor; HBd, hydrogen bond donor; HBSS, hanks’ balanced salt 46 
solution; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; hOATP, human organic anion 47 
transporting polypeptide; KHB, Krebs Henseleit buffer; Km, Michaelis-Menten constant; Kmenzyme, 48 
intracellular unbound enzymatic Km, Kmhep,u,ex, unbound extracellular Km for metabolism; Kpu,u, ratio 49 
of the intracellular to extracellular unbound concentration; L-15, Leibovitz; LogD, distribution 50 
coefficient; NADPH, nicotinamide adenine dinucleotide phosphate; NCE, new chemical entity; Papp, 51 
apparent permeability coefficient; PBS, phosphate buffered saline; pKa, acid dissociation constant; 52 
PSA, polar surface area; RLM, rat liver microsomes; SCRH, sandwich-cultured rat hepatocytes; SDS, 53 
sodium dodecyl sulfate; SRH, suspended rat hepatocytes; TPGS1000, D-α-tocopheryl polyethylene 54 
glycol 1000 succinate; WEM, Williams’ E medium; WST-1, water soluble tetrazolium-1 55 
  56 
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1. INTRODUCTION 57 
Many drug discovery programs start with the screening of large compound libraries (either corporate 58 
or commercially available compound collections) in an appropriate target- or cell-based assay. The 59 
selection of ‘hit’ compounds is usually based on the selective affinity of compounds for a target protein 60 
or the potency of the compounds in a phenotypic assay. In addition, it is also important that drug 61 
candidates possess the appropriate physicochemical properties, such that a safe delivery at the target 62 
site can be ensured to obtain efficacy in vivo and that the compound ultimately can be developed as a 63 
drug. This implies that a balance needs to be found between the biological activities and drug-like 64 
properties of the compound. Drug-like molecules are defined as compounds with acceptable 65 
absorption, distribution, metabolism and excretion properties, along with an acceptable toxicity 66 
(ADMET) (Fan and de Lannoy, 2014). Therefore, it is of utmost importance to evaluate drug-like 67 
properties in an early stage of drug-development to prevent high attrition rates due to unacceptable 68 
pharmacokinetics in a later stage (Wang and Urban, 2004). 69 
In silico determination of various physicochemical properties, such as the distribution coefficient 70 
(LogD) and the polar surface area (PSA) allow the rapid estimation of ADMET properties and have been 71 
very popular among medicinal chemists as they are easy to calculate (Lipinski et al., 2001). However, 72 
these predictions are not always consistent with experimental observations, indicating that application 73 
of appropriate in vitro models to study drug disposition is desirable. Among ADMET properties, hepatic 74 
drug clearance is one of the most important features to be predicted (Di et al., 2013). Over the past 75 
few decades, hepatic clearance has often been estimated using liver microsomes (Chiba et al., 2009; 76 
Obach, 1999). However, limitations of this in vitro model are the lack of non-microsomal enzymes and 77 
cellular context. Therefore, more biorelevant experimental models should be implemented to obtain 78 
insight in all processes underlying drug disposition and clearance. To predict oral drug absorption, 79 
intestinal solubility and permeability are commonly evaluated. Pre-clinical data regarding solubility, 80 
permeability and metabolism have previously been used to predict intestinal drug absorption and 81 
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overall drug disposition based on the biopharmaceutics classification system (BCS) and 82 
biopharmaceutics drug disposition classification system (BDDCS) (Larregieu and Benet, 2014). 83 
However, both systems require information regarding solubility based on the highest administered 84 
dose thus limiting the evaluation of new compound collections using these classifications. 85 
Traditional compound collections used for screening purposes consist of low molecular weight 86 
heterocycles, usually based on one or more (hetero) aromatic ring structures. In addition, there is a 87 
strong interest in the synthesis and biological evaluation of novel heterocycles as potential therapeutic 88 
agents (Jang et al., 2011). Therefore, a series of heterocycles synthesized during a drug discovery 89 
project (Figure 1) was presently used to evaluate applicability of different non-clinical models 90 
predicting ADMET properties. Since the fraction of the compound reaching the systemic circulation 91 
after oral administration is mainly influenced by processes occurring in the liver and intestine, this 92 
profiling study focused on the prediction of the hepatic and intestinal disposition. The information 93 
acquired from in vitro models was used to classify the heterocycles according to the BCS and BDDCS 94 
to predict drug disposition characteristics solely based on in vitro data. 95 
  96 
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2. MATERIALS & METHODS 97 
2.1. Chemicals 98 
The heterocycles were synthesized at the Laboratory of Medicinal Chemistry (Interface Valorisation 99 
Platform, IVAP, Sint-Rafaël, KU Leuven). Hanks’ balanced salt solution (HBSS), Williams’ E medium 100 
(WEM), Dulbecco’s modified Eagle’s medium (DMEM), phosphate buffered saline (PBS), 101 
penicillin/streptomycin (10,000 IU/mL, 10,000 μg/mL), nonessential amino acid medium (100x), L-102 
glutamine, fetal bovine serum (FBS) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 103 
were obtained from Lonza (Westburg, The Netherlands). Leibovitz (L-15) medium was acquired from 104 
Invitrogen (Carlsbad, CA). Simulated intestinal fluid (SIF) powder was purchased from Biorelevant 105 
(Croydon, UK). D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS1000) was obtained from 106 
Eastman Chemical Company (Kingsport, TN), acetic acid from Chem-lab (Zedelgem, Belgium). 107 
GF120918 (elacridar) was provided by GSK (London, UK). Water was purified with a Maxima system 108 
(Elga Ltd., High Wycombe Bucks, UK). Dimethyl sulfoxide (DMSO) and Triton X-100 were obtained from 109 
Acros Organics (Geel, Belgium), sodium dodecyl sulfate (SDS) and sodium hydroxide pellets from Merck 110 
(Darmstadt, Germany). Sodium acetate trihydrate, methanol and acetonitrile were purchased from 111 
VWR International (Leuven, Belgium), cell proliferation reagent water soluble tetrazolium-1 (WST-1) 112 
from Roche (Mannheim, Germany). Indinavir was donated by Hetero Drugs Ltd. (Hyderabad, India). All 113 
other chemicals were purchased from Sigma-Aldrich (St Louis, MO). 114 
2.2. In silico profiling 115 
Marvin Sketch was used to determine key physicochemical properties: hydrogen bond acceptors (HBa), 116 
hydrogen bond donors (HBd), rotatable bonds (RB), LogD (pH 7.4), PSA and acid dissociation constant 117 
(pKa). The liver-to-blood partition coefficients (Kliver:blood) were calculated according to Paixão et al. 118 
Descriptors, used to calculated Kliver:blood, were obtained with ALOGPS 2.1 program and E-Dragon 1.0 119 
software using SMILES converted to the 3D representation of the molecule with CORINA (Paixão et al., 120 
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2014). Human organic anion transporting polypeptide (hOATP) 1B-inhibition potential was predicted 121 
using a proteochemometrics-based in silico model (De Bruyn et al., 2013). 122 
2.3. Hepatic disposition profiling 123 
2.3.1. Hepatocyte isolation 124 
Hepatocytes were isolated from male Wistar rats (175-200 g) with a two-step collagenase perfusion as 125 
described previously (Annaert et al., 2001). Approval for the experiments was granted by the 126 
Institutional Ethical Committee for Animal Experimentation of the KU Leuven. After isolation, cells 127 
were centrifuged (50 g) for 3 min at 4°C and the pellet was resuspended in Krebs Henseleit buffer (KHB; 128 
130 mM NaCl, 5.17 mM KCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 12.5 mM HEPES, 11.1 mM glucose, 5 mM 129 
sodium pyruvate, pH 7.4), L-15 medium supplemented with 4 mM L-glutamine or seeding medium 130 
(WEM containing 2 mM L-glutamine, 100 IU/mL penicillin, 100 μg/mL streptomycin, 5 % FBS, 4 mg/L 131 
insulin and 1 μM dexamethasone). Viability was determined using the trypan blue exclusion method 132 
and was always higher than 85 %. 133 
2.3.2. In vitro intrinsic uptake clearance in suspended rat hepatocytes 134 
Experiments were conducted as described previously (De Bruyn, Fattah, et al., 2011). Briefly, 135 
suspended rat hepatocytes (SRH) (2x106 cells/mL) in KHB were pre-warmed at 37°C (500 μL). The 136 
incubation was initiated by adding 500 μL of a pre-warmed double-concentrated heterocycle solution 137 
(final concentration 8 μM). After 1 min, aliquots of 200 μL were transferred in triplicate to ice-cold 138 
microcentrifuge tubes (1.5 mL), containing 700 μL of an oil mixture (density 1.015; a mixture of silicone 139 
oil and mineral oil) above 300 μL of 8 % NaCl solution. Tubes were centrifuged at 14,000 rpm for 2 min 140 
and frozen on dry ice. After freezing, the tube bottoms were cut and the cell lysate was solubilized in 141 
300 μL methanol/water (70/30). Experiments were also performed at 4°C to determine nonsaturable 142 
uptake. Net uptake values were obtained by subtracting uptake in rat hepatocytes at 4°C from total 143 
uptake at 37°C. Subsequently, active, passive and total uptake clearance values (Clint,uptake; 144 
µl/min/million cells) were determined by dividing the net uptake, passive uptake or total uptake 145 
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(pmol/min/million cells) by the substrate concentration. Finally, Clint,uptake was converted from 146 
µL/min/million cells to mL/min/kg bodyweight using the scaling factors 120 million cells/g liver and 40 147 
g liver/kg body weight. 148 
2.3.3. In vitro intrinsic metabolic clearance in suspended rat hepatocytes 149 
Experiments were performed as described previously (Wuyts et al., 2013). Briefly, the incubation 150 
mixture consisted of the SRH (1x106 cells/mL) and heterocyclic compound (0.5-100 µM) in the presence 151 
or absence of 1-aminobenzotriazole (ABT; 1 mM) in L-15 medium supplemented with 4 mM L-152 
glutamine (500 μL). At 0, 45 and 120 min, aliquots (150 μL) were taken and added to methanol (300 153 
μL). Verapamil metabolism was determined as a positive control and incubations without cells were 154 
used as negative control. 155 
In vitro hepatic metabolism of the compounds was assessed with the ‘in vitro half-life (t1/2) method’ 156 
(Obach, 1999) using scaling factors (Chiba et al., 1997). Intrinsic metabolic clearance obtained in 157 
hepatocytes (Clint,met,hep) was determined using the following equation: 158 
𝐶𝑙𝑖𝑛𝑡,𝑚𝑒𝑡,ℎ𝑒𝑝 =
0,693
𝑡1/2
×
𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒
𝑚𝑖𝑙𝑙𝑖𝑜𝑛 𝑐𝑒𝑙𝑙𝑠
×
120 𝑚𝑖𝑙𝑙𝑖𝑜𝑛 𝑐𝑒𝑙𝑙𝑠
𝑔 𝑙𝑖𝑣𝑒𝑟
×
40 𝑔 𝑙𝑖𝑣𝑒𝑟
𝑘𝑔 𝑏𝑜𝑑𝑦𝑤𝑒𝑖𝑔ℎ𝑡
 159 
(Equation 1) 160 
For compound 1210, Michaelis-Menten parameters regarding the metabolic disappearance were 161 
determined by non-linear regression analysis in R (version i386 2.15.3). 162 
2.3.4. In vitro intrinsic metabolic clearance in rat liver microsomes 163 
Rat liver microsomes (RLM) were prepared according to in-house procedures (Nicolaï et al., 2015). 164 
Microsomal incubations were performed at 37°C and 350 rpm (Thermomixer, Eppendorf AG, Hamburg, 165 
Germany). The incubation mixture consisted of RLM (0.5 mg/mL) and heterocyclic compound (0.5-100 166 
μM) diluted in microsomal buffer (phosphate buffer (100 mM) containing MgCl2 (3 mM) pH 7.4). After 167 
a pre-incubation of 10 min, nicotinamide adenine dinucleotide phosphate (NADPH) (1 mM) and 168 
9 
 
glucose-6-phosphate (3 mM) were added to initiate the reaction. Reactions were terminated by taking 169 
samples (75 μL) at 0, 10, 20 and 30 min and adding them to acetonitrile (75 μL). 170 
In vitro hepatic metabolism of the compounds was assessed as described previously with the ‘in vitro 171 
t1/2 method’. Intrinsic metabolic clearance obtained in microsomes (Clint,met,mic) was determined as 172 
follows: 173 
𝐶𝑙𝑖𝑛𝑡,𝑚𝑒𝑡,𝑚𝑖𝑐 =
0,693
𝑡1/2
×
𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒
𝑚𝑔 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠
×
46 𝑚𝑔 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠
𝑔 𝑙𝑖𝑣𝑒𝑟
×
40 𝑔 𝑙𝑖𝑣𝑒𝑟
𝑘𝑔 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡
 174 
(Equation 2) 175 
For compound 1210 Michaelis-Menten parameters for the metabolic disappearance were determined 176 
by non-linear regression analysis in R (version i386 2.15.3). 177 
2.3.5. Determination of unbound fraction in plasma and microsomal binding 178 
The unbound fraction in plasma (fu) was determined for the heterocycles with equilibrium dialysis in 179 
the HTD96b setup from HTDialysis, LLC (Gales Ferry, CT, US). Pooled rat plasma (n=5) containing 180 
heterocyclic compound (8 μM) and PBS were added to the donor and acceptor compartment, 181 
respectively to determine plasma protein binding. For the microsomal binding, 0.5 mg/mL RLM in 182 
microsomal buffer containing heterocyclic compound (8 μM) was added to the donor compartment 183 
and microsomal buffer to the acceptor compartment. Samples (n=3) of both compartments were taken 184 
after a 6 h incubation at 37°C. The fu was determined using the following equation: 185 
𝑓𝑢 =  
[𝐶𝑜𝑚𝑝𝑜𝑢𝑛𝑑]𝑎𝑐𝑐𝑒𝑝𝑡𝑜𝑟
[𝐶𝑜𝑚𝑝𝑜𝑢𝑛𝑑]𝑑𝑜𝑛𝑜𝑟
 186 
(Equation 3) 187 
 188 
 189 
2.3.6. Ratio of the intracellular to extracellular unbound concentration. 190 
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The ratio of the intracellular to extracellular unbound concentration (Kpu,u) was determined according 191 
to Nicolaï et al. (Nicolaï et al., 2015). An apparent Michaelis constant (Km) was determined in 192 
hepatocytes (Kmhep) since metabolic enzymes reside inside hepatocytes. As only the unbound fraction 193 
(fuhep) will be able to enter hepatocytes, the unbound extracellular Km (Kmhep,u,ex) was determined:  194 
𝐾𝑚ℎ𝑒𝑝 × 𝑓𝑢ℎ𝑒𝑝 = 𝐾𝑚ℎ𝑒𝑝,𝑢,𝑒𝑥 195 
(Equation 4) 196 
In RLM, cytochrome P450 (CYP)-mediated metabolism is measured without restriction regarding 197 
membrane permeability. Therefore, intracellular unbound enzymatic Km (Kmenzyme) could be 198 
determined based on Km determined in microsomes (Kmmic) and the unbound fraction in microsomal 199 
incubations (fumic) because these enzymes are assumed to retain affinity for specific compounds 200 
(Nicolaï et al., 2015). Kmenzyme was determined as follows: 201 
𝐾𝑚𝑚𝑖𝑐 × 𝑓𝑢𝑚𝑖𝑐 = 𝐾𝑚𝑒𝑛𝑧𝑦𝑚𝑒 202 
(Equation 5) 203 
Consequently, in case of CYP-mediated metabolism, Kpu,u can be calculated: 204 
𝐾𝑚𝑒𝑛𝑧𝑦𝑚𝑒
𝐾𝑚ℎ𝑒𝑝,𝑢,𝑒𝑥
= 𝐾𝑝𝑢,𝑢 205 
(Equation 6) 206 
2.3.7. Canalicular and basolateral efflux in rat hepatocytes 207 
Canalicular and basolateral efflux were assessed in sandwich-cultured rat hepatocytes (SCRH). SCRH 208 
were cultured as described previously (Wuyts et al., 2013). Briefly, freshly-isolated hepatocytes were 209 
seeded on collagen coated 24-well plates at a density of 0.5 x 106 cells/well in seeding medium. Cells 210 
were allowed to attach for 1-2 h, after which the medium was aspirated to remove unattached cells. 211 
Cells were overlaid with collagen and, after one hour, seeding medium was added onto the SCRH. 212 
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Culture medium was replaced daily (WEM containing 2 mM L-glutamine, 100 IU/mL penicillin, 100 213 
μg/mL streptomycin, 1 % (v/v) ITSTM + Premix and 0.1 μM dexamethasone). 214 
On day 4, SCRH were rinsed twice and pre-incubated for 10 min with standard buffer (HBSS containing 215 
10 mM HEPES; pH 7.4; 37°C). Subsequently, hepatocytes were loaded with representative compound 216 
1269 (8 μM) in standard buffer for 15 min. Wells were washed three times and part of the cells were 217 
lysed with methanol/water (70/30) to determine accumulation after loading. Additionally, fresh 218 
standard or Ca++/Mg++-free-buffer (Ca++/Mg++-free HBSS containing 10 mM HEPES and 1 mM EGTA; pH 219 
7.4; 37°C) was added to the remaining wells. Samples of the buffer were taken after 15 min. Protein 220 
content was determined in three representative wells using a BCA Protein assay kit (Pierce Chemical, 221 
Rockford, Illinois).  222 
Canalicular efflux was determined by subtracting substrate efflux in standard buffer (tight junctions 223 
intact: efflux across basolateral membrane) from substrate efflux in Ca++/Mg++-free-buffer (tight 224 
junctions disrupted: efflux across both basolateral and canalicular membrane). Basolateral efflux was 225 
measured in standard buffer samples. Efflux was expressed as pmol/mg protein. 226 
In vitro intrinsic canalicular (Clint,canalicular) and basolateral clearance (Clint,basolateral) were determined as 227 
follows (Nakakariya et al., 2012): 228 
 𝐶𝑙𝑖𝑛𝑡,𝑐𝑎𝑛𝑎𝑙𝑖𝑐𝑢𝑙𝑎𝑟  𝑜𝑟 𝐶𝑙𝑖𝑛𝑡,𝑏𝑎𝑠𝑜𝑙𝑎𝑡𝑒𝑟𝑎𝑙 =
𝐶𝑎𝑛𝑎𝑙𝑖𝑐𝑢𝑙𝑎𝑟 𝑜𝑟 𝐵𝑎𝑠𝑜𝑙𝑎𝑡𝑒𝑟𝑎𝑙 𝑒𝑓𝑓𝑙𝑢𝑥
𝐼𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒 ∗  𝐶ℎ𝑒𝑝
 229 
(Equation 7) 230 
𝐶ℎ𝑒𝑝 =
𝐴𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑐𝑒𝑙𝑙𝑠 𝑎𝑓𝑡𝑒𝑟 𝑙𝑜𝑎𝑑𝑖𝑛𝑔
𝐼𝑛𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑣𝑜𝑙𝑢𝑚𝑒
 231 
(Equation 8) 232 
where efflux and accumulation in cells after loading were in pmol/mg protein, Chep was the 233 
concentration in hepatocytes and total intracellular volume was 5.2 µL/mg protein. Clint,canalicular and 234 
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Clint,basolateral were converted from µL/min/mg protein to mL/min/kg bodyweight using the scaling 235 
factors 200 mg protein/g liver and 40 g liver/kg body weight. 236 
2.3.8. Metabolic site prediction 237 
Metabolic sites of the heterocycle structures were predicted with MetaPrint2d (University of 238 
Cambrige) (http://www-metaprint2d.ch.cam.ac.uk/). The most frequently reported sites of 239 
metabolism are indicated by comparing the compounds with a database of structures with known 240 
metabolic patterns. Subsequently, the normalized occurrence ratio (NOR) is determined. 241 
2.3.9. In vitro – in vivo extrapolation (IVIVE) of hepatic clearance 242 
To evaluate the rate-limiting step in the overall hepatic elimination, the in vivo clearance of the 243 
heterocycles was predicted based on uptake data only (ClH,uptake), metabolism data only (ClH,met) or a 244 
combination of both (ClH). Therefore, previously determined intrinsic clearance values were converted 245 
to the hepatic in vivo clearance values with the well-stirred model (Webborn et al., 2007): 246 
 247 
(Equation 9) 248 
 249 
(Equation 10) 250 
 251 
(Equation 11) 252 
where QH is the hepatic plasma flow (28.3 mL/min/kg) in rat, fu is the unbound fraction in plasma, Clint 253 
is the in vitro intrinsic clearance and Clpassive is the passive uptake in hepatocytes (4°C). Finally extraction 254 
ratios (ER) were determined (ER = ClH/QH). The ER describes the efficiency of the hepatic drug 255 
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elimination process; ER values between 0-0.3 reflect poor elimination, 0.3-0.7 intermediate 256 
elimination and 0.7-1 extensive elimination (Wuyts et al., 2013). 257 
2.3.10. Hepatotoxicity 258 
To determine hepatotoxicity, compound (5 or 50 μM) in culture medium was added onto SCRH one 259 
day after seeding. The urea assay was performed after 6, 48 and 72 h to evaluate cellular integrity and 260 
biochemical functionality (Chatterjee et al., 2014). Briefly, cells were rinsed twice with standard buffer 261 
followed by a pre-incubation for 10 min at 37°C. Subsequently, hepatocytes were loaded with 262 
incubation buffer (standard buffer containing 2 mM L-glutamine, 10 mM ammonium chloride and 3 263 
mM ornithine) and incubated for 1 h at 37°C. Aliquots of the incubation buffer were taken and mixed 264 
with color reagent. The intensity of the color was measured spectrophotometrically at 525 nm. 265 
2.4. Intestinal disposition profiling 266 
2.4.1. Intraluminal solubility  267 
The solubility of the compounds was determined in biorelevant fasted state simulated intestinal fluid 268 
(FaSSIF), possessing mixed micelles of taurocholate and lecithin. FaSSIF which was prepared by 269 
dissolving 2.24 mg/mL SIF powder in a phosphate buffer, blank FaSSIF (3.95 mg/mL NaH2PO4.H2O, 6.19 270 
mg/mL NaCl, 0.42 mg/mL NaOH, pH 6.5), according to the manufacturer’s preparation protocol. The 271 
thermodynamic solubility was determined as described previously (Wuyts et al., 2013). Briefly, an 272 
excess of compound was added to FaSSIF (0.5 mg/300 µL). This suspension was shaken for 24 h at 175 273 
rpm and 37°C (KS 4000i Control incubator shaker, Staufen, Germany) and centrifuged at 20,817 g for 274 
15 min (5804 Centrifuge, Eppendorf, Hamburg, Germany) to remove undissolved drug. The 275 
supernatant was analyzed. 1351 and 1366 were excluded from further experiments due to extremely 276 
low solubility and chemical instability at 37°C, respectively. 277 
 278 
 279 
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2.4.2. Intestinal permeability 280 
Intestinal permeability was determined as described previously (Wuyts et al., 2013). Briefly, Caco-2 281 
cells were grown in DMEM supplemented with 10 % FBS, 1 % nonessential amino acid, 100 IU/mL 282 
penicillin and 100 μg/mL streptomycin at 37°C, in a humidified atmosphere with 5% CO2. Cells were 283 
seeded at a density of 90,000 cells/cm2 on Costar Transwell membrane inserts (3 µm pore diameter, 284 
12 mm diameter; Corning Inc., Corning, NY) and were used in transport studies 17 to 18 days after 285 
seeding. Transport medium (HBSS supplemented with 25 mM glucose and 10 mM HEPES at pH 7.4) 286 
containing 0.2 % TPGS1000 was used in the basolateral compartment to create sink conditions and 287 
solubilize the drugs. The experiment was initiated by adding FaSSIF (pH 6.5) containing the 288 
heterocycles (10-100 µM) in absence or presence of P-gp-inhibitor GF120918 (4 µM), to the apical 289 
compartment. Samples were shaken at 300 rpm for 1h at 37°C (Thermostar, BMG Labtech, Offenburg, 290 
Germany).  291 
The apparent permeability coefficient (Papp) was calculated according to the following equation: 292 
 293 
(equation 12) 294 
where Q is the cumulative amount of drug appearing in the acceptor compartment, A is the surface 295 
area of the Transwell membrane (1.13 cm2), and Cdonor is the initial drug concentration in the apical 296 
compartment. 297 
2.4.3. Intestinal toxicity 298 
Caco-2 cells were seeded at a density of 90,000 cells/cm² on flat bottom 96-well culture plates. 299 
Confluence was reached after 3-4 days in a CO2 incubator at 37°C. 300 
 301 
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A. Water-soluble tetrazolium-1 (WST-1) viability assay 302 
Caco-2 cells were incubated for 24 h at 37°C with 200 µL heterocycle solution (50 μM) in DMEM 303 
supplemented with 10 % FBS, 1 % nonessential amino acid, 100 IU/mL penicillin and 100 μg/mL 304 
streptomycin. The positive control consisted of 1 % SDS; blank medium was used as negative control. 305 
Subsequently, 20 µL of WST-1 cell proliferation reagent was added and the incubation was continued 306 
for 3 h. Absorbance was measured at 440 nm against a 630 nm reference with a TECAN Infinite M200 307 
plate reader (Tecan Benelux, Mechelen, Belgium).  308 
B. Lactate dehydrogenase (LDH) toxicity assay 309 
Caco-2 cells were incubated for 24 h at 37°C with 200 µL heterocycle solution (50 µM) in HBSS 310 
supplemented with 25 mM glucose and 10 mM HEPES at pH 7.4. The positive control consisted of 1 % 311 
Triton-X 100; blank medium was used as negative control. Subsequently, 50 µL of Tris buffer (200 mM, 312 
pH 8), 50 µL sodium lactate (50 mM) and 50 µL of a mixture of phenazine methosulfate (0.9 mg/100 313 
µL water), iodonitrotetrazolium chloride (3.3 mg/100 µL DMSO) and β-Nicotinamide adenine 314 
dinucleotide sodium salt from Saccharomyces cerevisiae (8.6 mg/2.3 mL water) were added to 50 µL 315 
of samples or control. After 10 min at room temperature absorbance was measured at 490 nm. 316 
2.5. Classification of heterocycles in BCS and BDDCS 317 
Heterocycles were categorized in the BCS and BDDCS based on their solubility, permeability and 318 
metabolism. Therefore, compounds were ranked according to these properties. Firstly, solubility was 319 
considered high (≥ 500 mg/250 mL), intermediate (10 mg/250 mL < x < 500 mg/250 mL) or poor (≤ 10 320 
mg/250 mL). This type of non-binary classification approach was proposed recently (Macheras and 321 
Karalis, 2014). We propose these threshold values based on the highest doses of the 10 most 322 
prescribed drugs in the United States (www.imshealth.com). Secondly, high permeability was assumed 323 
at Papp values ≥ 10x10-6 cm/s in the Caco-2 model since the fraction absorbed in human associated with 324 
these permeability values was shown to be at least 90% based on data in our lab (Ingels et al., 2004). 325 
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For metabolism, ER was determined with the well-stirred model based on the ClH,met, as described in 326 
section 2.3.9. Subsequently, metabolism was considered high (ER > 0.7), intermediate (0.3 ≤ ER ≤ 0.7) 327 
or poor (< 0.3). In the BCS, heterocycles were categorized based on solubility and permeability: Class I 328 
(high solubility, high permeability), Class II (low solubility, high permeability), Class III (high solubility, 329 
low permeability) and Class IV (low solubility, low permeability). In the BDDCS, the compounds were 330 
classified based on solubility and metabolism: Class I (high solubility, extensive metabolism), Class II 331 
(low solubility, extensive metabolism), Class III (high solubility, poor metabolism) and Class IV (low 332 
solubility, poor metabolism) (Larregieu and Benet, 2014; Wu and Benet, 2005). 333 
2.6. Glomerular filtration 334 
Renal clearance through glomerular filtration (Clrenal,filtration) was calculated as follows: 335 
𝐶𝑙𝑟𝑒𝑛𝑎𝑙,𝑓𝑖𝑙𝑡𝑟𝑎𝑡𝑖𝑜𝑛 = 𝑓𝑢 x GFR 336 
(Equation 14) 337 
where GFR is the glomerular filtration rate in rats which was 1.31 mL/min in rats of 180 g (Davies and 338 
Morris, 1993). 339 
2.7. HPLC analysis 340 
The HPLC system used to analyze the heterocyclic compounds consisted of a Waters 2790 Alliance 341 
series separations module and a Novapak C18 column under radial compression (Waters, Milford, MA). 342 
UV absorbance was monitored using a Waters 2487 detector and fluorescence using a FP-1520 343 
intelligent fluorescence detector (Jasco, Tokyo, Japan). The observed peaks were integrated using 344 
Empower Pro (Empower 2) software. The calibration curves of the heterocycles were linear over the 345 
concentration range of 0.78 µM to 100 µM. The different HPLC methods of heterocycles are listed in 346 
supplemental Table 1. 347 
2.8. Statistics 348 
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Statistical analysis was performed using a two-tailed unpaired t-test. P-values of less than 0.05 are 349 
considered statistically significant. 350 
In the hepatotoxicity assay, urea production in treated cells is expressed as fold change versus the 351 
untreated situation. Functionality and integrity of treated cells were considered significantly decreased 352 
when mean (+/- 95% C.I.) residual urea production fell below 67% of control values (test/reference 353 
ratio ≤ 2/3). 354 
The Tanimoto coefficient was determined to evaluate similarity between compounds. This parameter 355 
is defined as c/(a+b+c), which is the proportion of the features shared among two compounds divided 356 
by their union. The number of features (or on-bits in binary fingerprint) common in both compounds 357 
is indicated by c. The number of features unique in one or the other compound are indicated by a and 358 
b, respectively. The Tanimoto coefficient ranges between 0 and 1 with greater similarities indicated 359 
with higher values (Wuyts et al., 2013).  360 
18 
 
3. RESULTS 361 
3.1. In silico profiling 362 
Key physicochemical properties of the heterocycles are depicted in Table 1.  363 
3.2. Hepatic disposition profiling 364 
3.2.1. In vitro intrinsic uptake clearance in suspended rat hepatocytes 365 
Hepatic uptake of all heterocycles at 37°C and 4°C in SRH is shown in Figure 2. For 1210, 1211, 1214, 366 
1269, 1271, 1348, 1350, 1396, 1398 and 1399, a significant difference was observed between 37°C and 367 
4°C, indicating possible involvement of active uptake transporters. Therefore, these compounds were 368 
checked for hOATP1B-inhibition potential using a proteochemometrics-based in silico model (De Bruyn 369 
et al., 2013). However, none of the compounds was predicted to be a hOATP1B-inhibitor. To compare 370 
uptake rates from marker drugs from different BDDCS classes with the heterocycles, Figure 2 also 371 
includes marker drug from the four BDDCS classes (1) propranolol, (2) atorvastatin, (3) valsartan and 372 
(4) digoxin (Umehara and Camenisch, 2012). Only 1210 and 1367 exhibited uptake rates in the same 373 
range as these compounds; uptake of all other heterocycles was more pronounced. 374 
3.2.2. In vitro intrinsic metabolic clearance in rats 375 
Clint,met of the heterocycles was determined in microsomes and hepatocytes. There was a poor 376 
correlation between Clint,met,hep and Clint,met,mic, as illustrated in Figure 3. However, the generated data 377 
allow the classification of these compounds in different groups: (i) compounds only metabolized in 378 
hepatocytes, (ii) compounds more extensively metabolized in hepatocytes as compared to 379 
microsomes, (iii) compounds more extensively metabolized in microsomes as compared to 380 
hepatocytes and (iv) compounds that show a good correlation between Clint,met,hep and Clint,met,mic. 381 
Metabolic clearance of 1210, a chosen representative of the second group, was mainly mediated by 382 
cytochrome P450 (CYP) enzymes since 91% of metabolism was inhibited in the presence of ABT. 383 
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Therefore, a Kpu,u value of 4.77 could be calculated based on fu and Km values determined with 384 
microsomes and hepatocytes, shown in Table 2, indicating an accumulation of this compound in the 385 
intracellular compartment. 1269 was selected as a representative for the third group in which 386 
compounds are more extensively metabolized in microsomes compared to hepatocytes. Since efflux 387 
from hepatocytes could explain the inconsistency, canalicular and basolateral efflux were evaluated. 388 
However, no canalicular and limited basolateral clearance (0.44 ± 0.07 mL/min/kg bodyweight) of 1269 389 
was observed. 390 
3.2.3. Metabolic site prediction 391 
MetaPrint2d was used to predict anilines, thiophenes and thiazoles to be most prone to metabolism 392 
for the heterocyclic compounds (Figure 4). 393 
3.2.4. In vitro – in vivo extrapolation (IVIVE) of clearance in rats 394 
To determine the rate-limiting step in the overall hepatic elimination of the heterocycles, in vivo 395 
hepatic clearance was predicted with the well-stirred model using Clint,uptake, Clint,met,hep or a combination 396 
of both. With the exception of 1210, total hepatic elimination of the heterocycles was poor or 397 
intermediate as indicated by the ER (Table 3). A weak correlation was observed between ClH and 398 
ClH,uptake (R2= 0.57; Figure 5A). On the contrary, a strong correlation was observed between ClH and 399 
ClH,met (R2= 0.96; Figure 5B), indicating that metabolism is the rate-limiting step in hepatic elimination 400 
of these heterocycles. 401 
3.2.5. Hepatotoxicity 402 
Hepatotoxicity data is shown in Figure 6. For 12 compounds after 6-72 h incubation periods, the urea 403 
production by hepatocytes was not significantly different from control. However, mean ratios of urea 404 
levels in cells treated with 50 μM of 1349, 1350, 1352 and 1365 were significantly decreased after 48 405 
h. Except for wells incubated with 1365, in which hepatocytes recovered, these cells showed 406 
hepatotoxicity after 72 h as well. Cells treated with 1213 started to show toxicity after 72 h of 407 
20 
 
treatment. Conversely, treatment of cells with 5 μM of compound did not influence the urea 408 
production compared to the control situation for all heterocycles. 409 
3.3. Intestinal disposition profiling 410 
3.3.1. Intraluminal solubility  411 
Figure 7 illustrates a broad range in solubility values of the heterocycles in FaSSIF, ranging from 0.40 ± 412 
0.03 mg/250 mL for 1399 to 718 ± 133 mg/250 mL for 1210. 413 
3.3.2. Intestinal permeability 414 
Similar as for the intraluminal solubility, a broad range was observed for permeability, as shown in 415 
Figure 8 with Papp values ranging from 65.7 ± 5.6 x 10-6 cm/s for 1271 to 7.4 ± 1.4 x 10-6 cm/s for 1348. 416 
No significant increase in Papp values was observed in the presence of P-gp inhibitor GF120918 417 
indicating that intestinal absorption is not influenced by P-gp. Papp values of all heterocycles were 418 
higher than that of the paracellular marker atenolol (0.19 x 10-6 cm/s). Permeability for 6 heterocycles 419 
was lower than that for the transcellular marker metoprolol (14.1 x 10-6 cm/s; 1211, 1348, 1349, 1367, 420 
1398, and 1399) whereas all other compounds exhibited higher Papp values (Figure 8). 421 
3.3.3. Intestinal toxicity 422 
No toxicity was observed with the WST-1 and LDH assay in Caco-2 cells treated with 50 μM of the 423 
heterocycles for 24 h (data not shown). 424 
3.4. Classification of heterocycles in BCS and BDDCS 425 
Classification of the heterocycles in terms of their solubility, permeability and metabolism is shown in 426 
Table 4. Since no biological activity has been determined for these compounds, solubility based on the 427 
therapeutic dose was impossible to determine. Therefore, threshold values were selected to 428 
determine high (≥ 500 mg/250 mL), intermediate (10 mg/250 mL < x < 500 mg/250 mL) or poor (≤ 10 429 
mg/250 mL) solubility. According to BCS, 1210 exhibited high intestinal solubility and permeability and 430 
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could therefore be ranked as a Class I compound. 1271 and 1396 showed intermediate solubility and 431 
could either be categorized in Class I or II. All other compounds were Class II compounds, indicating 432 
low solubility and high permeability, although 1211, 1348, 1349 and 1399 could also be Class IV 433 
compounds since their permeability was only intermediate. 434 
Since most compounds exhibited both poor solubility and poor metabolism, almost all heterocycles 435 
were classified as Class IV compounds in BDDCS. However, due to its extensive metabolism and high 436 
solubility, 1210 was considered as a Class I compound. Intermediate metabolism was observed for 437 
1214 and 1270; hence these compounds could be classified under Class II or IV. Conversely, 1271 438 
showed intermediate solubility and could therefore be either Class III or IV. Finally, both solubility and 439 
metabolism were intermediate for 1396; consequently this heterocycle can belong to all four classes. 440 
  441 
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4. DISCUSSION 442 
The aim of this study was to apply pre-clinical models to predict ADMET properties of 19 heterocycles 443 
with structures that frequently occur in drugs and lead compounds (e.g. duloxetine, clopidogrel) 444 
(Gomtsyan, 2012).Adequate in vitro models were used to determine the compounds’ intestinal 445 
solubility and permeability and hepatic metabolism to classify the compounds according to BCS and 446 
BDDCS and predict oral absorption and hepatic elimination. 447 
In silico determination of physicochemical properties predicted all compounds to be conform with 448 
Lipinski’s rule of five (Lipinski et al., 2001) (Table 1), indicating that based on (i) the amount of HBa and 449 
HBd; (ii) MW , and (iii) LogD poor intestinal absorption and permeation are unlikely (Lipinski et al., 450 
2001). In addition, the low number of rotatable bonds (<10) and PSA-values of 140 Å2 or less indicated 451 
good oral bioavailability (Veber et al., 2002). However, despite favorable physicochemical properties, 452 
extensive biopharmaceutical profiling was considered necessary to accurately predict ADMET 453 
properties. 454 
First, hepatic disposition was evaluated. Hepatic uptake, measured in suspended hepatocytes, was 455 
mainly passive (Figure 2) for these relatively small compounds which are neutral at physiological pH, 456 
since uptake was relatively high at 4˚C. However, uptake of ten compounds was significantly decreased 457 
at this low temperature indicating that active transport might be involved. It should be noted that a 458 
major limitation of this method is the altered membrane fluidity at 4°C which could limit the uptake 459 
(Zamek-Gliszczynski et al., 2013). Although transporters involved in heterocycle uptake have not been 460 
identified, the compounds were evaluated in a proteochemometrics-based in silico model to check for 461 
hOATP-inhibition potential. None of the compounds was expected to inhibit isoform 1B1 or 1B3 of this 462 
transporter which are mainly susceptible to anionic compounds (De Bruyn et al., 2013). 463 
Hepatic metabolic stability was investigated in RLM and SRH. As shown in Figure 3, a poor correlation 464 
was observed between the different in vitro systems. However, the plot allowed a classification of the 465 
heterocycles in groups: (i) compounds which were only metabolized in hepatocytes; (ii) compounds 466 
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more extensively metabolized in hepatocytes compared to microsomes; (iii) compounds more 467 
extensively metabolized in microsomes compared to hepatocytes and (iv) compounds that showed a 468 
good correlation between Clint,met,hep and Clint,met,mic. Although microsomes have been the principal 469 
model to study metabolic clearance, they show some disadvantages which could explain the 470 
inconsistency depicted in Figure 3. First of all, microsomes do not contain cytosolic enzymes, in 471 
particular most phase II enzymes (e.g. N-acetyltransferases or sulfotransferases). Moreover, uridine 472 
5'-diphospho-glucuronosyltransferases are only active in the presence of their co-factor. This might 473 
result in the limited microsomal metabolism of compounds from the first and second group (Obach, 474 
1999; Parker and Houston, 2008). For these compounds, hepatocytes containing all hepatic enzymes 475 
should be considered to evaluate metabolic stability in addition to microsomes. However, despite their 476 
biorelevance and the increasing importance of phase II enzymes in the elimination of NCE’s, a major 477 
drawback of using hepatocytes is the availability and cost of human hepatocytes. Despite the presence 478 
of multiple sites potentially susceptible to metabolism (Figure 4), compounds 1348, 1349 and 1399 are 479 
not metabolized in microsomes and only poorly in hepatocytes (Figure 3). Consequently, alternative 480 
methods should be considered to evaluate the turnover of those slowly metabolized compounds. The 481 
relay method, using several batches of thawed hepatocytes could be applied. Alternatively, hepatocyte 482 
culture systems with sustained drug-metabolizing activities might be used (Di and Obach, 2015). In 483 
addition to the absence of certain enzymes, microsomes lack cellular context and therefore ignore the 484 
possible role of membrane transporters (Ito and Houston, 2004; Parker and Houston, 2008; Webborn 485 
et al., 2007). Hence, concentrations at the enzyme level in microsomes are equal to the applied 486 
concentrations during the incubation. On the contrary, in hepatocytes, accumulation of compound at 487 
the enzyme site could occur which possibly enhances the apparent intrinsic clearance in this model 488 
system (Chu et al., 2013). Indeed, table 1 predicted hepatic accumulation of all heterocycles studied 489 
here (Kliver:blood > 1). Interestingly, accumulation of unbound 1210, a representative from group 2 in 490 
Figure 3, occurred. This heterocycle showed a Kpu,u value of 4.77, which explains the increased 491 
metabolism of this compound in hepatocytes since unbound compound, which is considered to be the 492 
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relevant fraction of compound interacting with metabolizing enzymes, is reaching almost 5-fold higher 493 
concentrations inside hepatocytes. On the contrary, a lower concentration at the enzyme level in 494 
hepatocytes compared to microsomes was proposed for group 3 in Figure 3. These lower 495 
concentrations could occur when efflux predominates; however efflux was only limited for compound 496 
1269. Alternatively, extensive intracellular binding or sequestration in organelles could also limit 497 
compound availability for enzymes. Therefore, accurate knowledge regarding intracellular drug 498 
exposure in addition to systemic (plasma) exposure is crucial to gain mechanistic understanding of 499 
drug exposure to metabolizing enzymes (Nicolaï et al., 2015). 500 
Metaprint2d predicted a high likelihood of metabolism on anilines, thiophenes and thiazoles (Figure 501 
4). The aniline moiety was present in both 1210 and 1396. Since no degradation of 1396 was observed 502 
in microsomes, non-microsomal metabolism (e.g. phase II) is most likely for this compound. Possible 503 
phase II reactions on anilines are acylation, glucuronidation and formylation. Interestingly, although 504 
phase I metabolism was predicted for all compounds in the first group, no metabolism could be 505 
observed in microsomes. However, it should be noted that the findings of this prediction model are 506 
restricted to the number and diversity of compounds used in the database to construct the model 507 
(http://www-metaprint2d.ch.cam.ac.uk/). 508 
IVIVE has successfully been applied for compounds of which elimination is predominantly mediated by 509 
uptake transporters or metabolic enzymes (Ito and Houston, 2004; Watanabe et al., 2010). However, 510 
the clearance of most compounds results from a complex interplay between both processes. 511 
Therefore, models have been developed implementing multiple processes of hepatic elimination 512 
(Umehara and Camenisch, 2012; Webborn et al., 2007). To evaluate the rate-limiting step in the overall 513 
hepatic elimination, the in vivo clearance of the heterocycles was predicted with the well-stirred-514 
model based on uptake, metabolism or a combination of both. Hepatic clearance based on uptake data 515 
resulted in a poor correlation (R2=0.57) with hepatic clearance based on the combination of both 516 
processes. Hepatic clearance based on uptake over-predicted the total hepatic clearance (Figure 5A). 517 
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Conversely, in vivo hepatic clearance based on metabolism resulted in a strong correlation (R2=0.96) 518 
with the hepatic clearance based on a combination of uptake and metabolism, suggesting that hepatic 519 
metabolism was more important in the hepatic elimination (Figure 5B). Consequently, drug-drug-520 
interactions at the enzyme-level may be anticipated for these heterocycles. Subsequently, ER were 521 
calculated based on total hepatic in vivo clearance predictions. Poorly cleared compounds are 522 
favorable when side effects are not an issue and when prolonged contact with the target is necessary 523 
for the treatment. Extensively cleared compounds could be useful when inactive prodrugs need to be 524 
converted into active metabolites. Compound 1210 is the only compound for which extensive 525 
clearance was predicted. Metabolism of this compound in hepatocytes was relatively high as indicated 526 
in Figure 3. Moreover, plasma protein binding of 1210 (69%) was relatively low as compared to the 527 
other compounds (86-99%). Since biological activity of the heterocycles still needs to be evaluated, 528 
compounds with poor or intermediate ER are most promising for once daily dosing regimens. 529 
Hepatotoxicity of the heterocycles was determined in SCRH with a urea assay, evaluating biochemical 530 
integrity and functionality of hepatocytes (Chatterjee et al., 2014). For 1349, 1350 and 1352 toxicity 531 
was observed when cells were incubated for 48 and 72 h with 50 μM of the compound, indicated by a 532 
significant decrease (> 33 %) in urea production. The urea production in cultures treated with 1213 533 
decreased over time as well. However, this reduction was only significant after 72 h. Interestingly, 534 
toxicity for 1365 was observed after 48 h, but not after 72 h meaning the cells recovered after the 535 
second urea assay. This recovery can imply that the observed toxicity resulted from exposure to a 536 
phase I metabolite which is subsequently eliminated by phase II metabolism. None of the compounds 537 
were considered toxic after incubations with 5 μM. 538 
Intestinal solubility and permeability were determined to evaluate pre-systemic disposition using 539 
FaSSIF, containing mixed micelles of taurocholate and lecithin. We previously demonstrated a strong 540 
correlation between solubility in FaSSIF and fasted state human intestinal fluid for 17 model 541 
compounds (Clarysse et al., 2011). Notwithstanding similar physicochemical properties, the different 542 
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substitutions had a major effect on the solubility of the heterocycles, demonstrated by a broad range 543 
in solubility values, ranging from 0.40 ± 0.03 mg/250 mL to 718 ± 133 mg/250 mL. For example, a furan 544 
moiety on 1352 resulted in an 11-fold higher solubility compared to the more lipophilic thiophene 545 
group in 1348 (Tanimoto coefficient 0.85). A similar difference between 1271 and 1211 changed the 546 
solubility 2.3-fold (Tanimoto coefficient 0.81). On the contrary, the effect on solubility of an altered 547 
bicyclic moiety on structurally similar molecules was less pronounced (e.g. 1269 and 1349 or 1350 and 548 
1365). Moreover, prolongation of the aliphatic chain in 1269 and 1270 compared to 1211 and 1214 549 
resulted in a 4- and 7-fold increase in solubility, respectively. These pairs of compounds exhibit the 550 
same physicochemical properties, as illustrated in Table 1, except for the number of RB. The extra RB 551 
resulted in more flexible molecules that could adapt their conformation to the polarity of the 552 
environment (e.g. FaSSIF medium) which can explain the increase in solubility (Navia and Chaturvedi, 553 
1996). As indicated in Figure 7, most heterocycles are classified as poorly soluble compounds and 554 
hence predisposed to low oral bioavailability. However, highly soluble compounds are preferred to be 555 
enrolled in the drug development process. Nevertheless, the improved understanding of approaches 556 
that promote solubility in the gastrointestinal tract has allowed the successful introduction of many 557 
drugs that are considered poorly soluble on the market (Williams et al., 2013) The approaches include 558 
particle size reduction, modification of the crystal habit, complexation, drug dispersion in carriers, the 559 
addition of surfactans or chemical modifications (Singh et al., 2011; Williams et al., 2013).Intestinal 560 
permeability was also highly affected by the substitutions present in the heterocyclic structures, 561 
resulting in a broad range of Papp values. Permeability of all heterocycles was higher than that of the 562 
paracellular marker atenolol (0.19x10-6 cm/s). For 6 heterocycles Papp was lower than that of the 563 
transcellular marker metoprolol (Figure 8: 1211, 1348, 1349, 1367, 1398 and 1399) whereas all other 564 
compounds showed higher Papp values (Figure 8). Based on previous data from our lab, compounds 565 
with Papp values of 10x10-6 cm/s and higher are considered to exhibit a fraction absorbed in human of 566 
at least 90% (Ingels et al., 2004). Therefore, 13 heterocycles were expected to be well absorbed (Figure 567 
8). Moreover, the intestinal absorption of none of the compounds will be limited by the efflux 568 
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transporter P-gp since their permeability was unaffected in the presence of P-gp-inhibitor GF120918 569 
(elacridar). In general, high permeability is observed for more lipophilic compounds. However, the Papp 570 
values determined for 1211 and 1348 were markedly lower than for 1271 and 1352 although the latter 571 
were more hydrophilic. A possible explanation may be that the lipophilic 1211 and 1348 reside in the 572 
micelles of the medium, lowering the free fraction of compound available for permeation across the 573 
Caco-2 monolayer. 574 
Heterocycles were categorized according to BCS and BDDCS which are useful tools in early stages of 575 
drug discovery (Table 4). These classifications predict absorption and routes of drug elimination 576 
respectively. Originally a compound was defined as ‘highly soluble’ when the highest dose strength on 577 
the market is soluble in 250 mL or less of aqueous medium (Wu and Benet, 2005). However, since no 578 
biological activity for these heterocycles has been determined yet, we propose threshold values based 579 
on the highest doses of 10 most prescribed drugs in the United States (www.imshealth.com). All 580 
categories contained compounds from this list: (i) highly soluble compounds (≥500 mg/250 mL): 581 
acetaminophen, metformin, azithromycin; (ii) intermediately soluble compounds (10 mg/250 mL < x < 582 
500 mg/250 mL): simvastatin, lisinopril, omeprazole; and (iii) poorly soluble compounds (≤10 mg/250 583 
mL): hydrocodone, levothyroxine, amlodipine and alprazolam. Moreover, the ranking allowed 584 
application of BCS and BDDCS for NCE’s, prior to in vivo administration in humans. Importantly, when 585 
dosages of these compounds appear to be relatively low, heterocycles may have to be considered 586 
highly soluble instead of poorly or intermediately soluble. With respect to permeability, metoprolol 587 
has previously been chosen as a high permeability reference cut-off for 90% absorption of the oral 588 
dose (Larregieu and Benet, 2014). However, since metoprolol possibly resides in micelles of the FaSSIF 589 
medium used in this study we used a cut-off Papp value of 10x10-6 cm/s or higher in Caco-2 cells as 590 
described earlier (Ingels et al., 2004). An ER of >70% calculated with the Clint,met,hep in the well-stirred 591 
model indicated extensive metabolism (Wuyts et al., 2013). 592 
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It has been suggested that BCS Class I and II compounds are extensively metabolized. Indeed, 593 
metabolism of 1210 will not be limited by solubility or permeability and is considered a Class I 594 
compound in both BCS and BDDCS. Nevertheless, regardless of high permeability, most heterocyclic 595 
compounds were poorly metabolized. Therefore, most heterocycles were class IV compounds in the 596 
BDDCS whereas the BCS mainly resulted in class II compounds. 597 
Class IV compounds are expected to be excreted unchanged. However, no canalicular excretion has 598 
been detected for compound 1269 and the molecular weight of the compounds were below the cut-599 
off value above which biliary excretion is expected (Yang et al., 2010). Moreover, renal clearance 600 
through glomerular filtration was relatively low compared to hepatic clearance (Supplemental Table 601 
2). Nevertheless, active processes in the kidney could still be involved. Furthermore, poor metabolism 602 
for compounds with a high permeability rate as well as high hepatic uptake might be explained by 603 
extensive intracellular binding or organelle sequestration. Moreover, the inconsistency between the 604 
BCS and BDDCS could result from the binary structure of these systems. For compound classification, 605 
the criteria solubility, permeability and metabolism are evaluated as either high/low or 606 
poor/extensive. However, a continuity for these properties has been observed in the current study 607 
(Figure 3, 7 and 8) as well as in previous research (Macheras and Karalis, 2014). Therefore, the 608 
classification of a large number of compounds in the BCS and BDDCS, specifically compounds with 609 
moderate solubility, permeability or metabolism, is uncertain. Consequently, systems with a 610 
continuous nature have been developed which are complementary to the conventional binary 611 
systems. For example, Macheras and Karalis introduced the ABΓ system that allowed the prediction of 612 
the fraction of the dose absorbed (Fa) in a quantitative manner for compounds with low, moderate 613 
and high solubility or permeability in classes A (Fa ≥ 0.90), Γ (0.20 ≥ Fa ≥ 0.90) and B (Fa ≤ 0.20). 614 
Notwithstanding the authors compared the ABΓ system to the BCS, their findings can also be related 615 
to the BDDCS as permeability in the BCS was replaced by metabolism in the BDDCS (Macheras and 616 
Karalis, 2014). The non-binary character of the ABΓ system provides extra information regarding the 617 
fraction absorbed which more accurately predicts this parameter for compounds with moderate 618 
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solubility, permeability and metabolism in particular. In addition, the ABΓ system facilitates the 619 
understanding of the discrepancy between BCS and BDDCS. Finally, it should be noted that the in vitro 620 
models used for the classification originate from different species. The Caco-2 cells used to determine 621 
intestinal permeability is a human cell line derived from colonic adenocarcinoma while metabolism 622 
studies have been performed in rat hepatocytes. Species-specific differences can be expected although 623 
poor metabolism in rat probably indicates poor metabolism in human since rodents tend to eliminate 624 
drugs faster than humans (Martignoni et al., 2006). 625 
5. CONCLUSION 626 
In addition to microsomes, hepatocytes should be included as a standard in vitro model system to 627 
cover potential involvement of phase II enzymes and cellular accumulation of unbound compound due 628 
to transporter-mediated processes. Therefore, accurate knowledge regarding intracellular drug 629 
exposure should be obtained with methods that allow measurements of the unbound drug 630 
concentrations in intact hepatocytes. Additionally, the in vitro data regarding solubility, permeability 631 
and metabolism was used for the the classification of NCE’s in the BCS and BDDCS to predict drug 632 
disposition characteristics before clinical data is available. 633 
Most heterocycles evaluated in this study show reasonable drug-like properties. At the level of the 634 
intestine, 13 compounds demonstrated high permeability (>10x10-6 cm/s) and no toxicity. The limited 635 
solubility could be overcome by proper formulation strategies. At the hepatic level, compounds were 636 
taken up easily and metabolism, which was intermediate or poor (except for 1210), was the rate-637 
limiting step in the elimination. Hepatotoxicity was limited at 50 µM and absent at 5 µM. The 638 
compounds were mainly classified as class II compounds in BCS and class IV compounds in BDDCS.  639 
30 
 
6. LEGENDS 640 
Figure 1: Chemical structures of the heterocycles investigated in the present study. 641 
Figure 2: Accumulation of heterocycles in suspended rat hepatocytes following uptake (1 min; 8 μM) 642 
at 37°C (black bars) and 4°C (white bars) is presented as the mean + S.D. (n=3). Marker drugs from 643 
different BDDCS classes are shown: (1) propranolol, (2) atorvastatin, (3) valsartan and (4) digoxin 644 
(Umehara and Camenisch, 2012).  645 
Figure 3: Scaled intrinsic clearance of the heterocycles determined in rat hepatocytes versus rat liver 646 
microsomes (8 µM). The solid line represents identical values in both model systems. Group I – IV are 647 
indicated in boxes. 648 
Figure 4: Prediction of most likely metabolized sites of the heterocycles using Metaprint2d. Normalized 649 
occurrence ratios (NOR) were indicated: 1:0.66 ≤ NOR ≤ 1; 2:0.33 ≤ NOR ≤ 0.66 and; 3:0.15 ≤ NOR ≤ 650 
0.33. Group I – IV are indicated. 651 
Figure 5: Relationship between intrinsic in vivo clearance values based on uptake data only (ClH,uptake) 652 
versus the combination of uptake and metabolism (ClH) (A) or metabolism data only (ClH,met) versus ClH 653 
(B).The solid line represents the regression curve and the dashed lines the plasma flow in rats. 654 
Figure 6: The mean ratio of urea production in treated vs. control cells + 95% C.I. (n=3). A urea assay 655 
was performed after incubation with 50 µM of the heterocycles for 6 (black bars), 48 (grey bars) and 656 
72 (white bars) h. 657 
Figure 7: Solubility of the heterocycles (mg/250 mL) and metoprolol in FaSSIF is presented as the mean 658 
+ S.D. (n=3). Solubility was considered high (≥ 500 mg/250 mL), intermediate (10 mg/250 mL < x < 500 659 
mg/250 mL) or poor (≤ 10 mg/250 mL). 660 
Figure 8: Absorption potential of the heterocycles and marker drugs in FaSSIF using the Caco-2 model 661 
in absence (black bars) and presence (white bars) of 4µM P-glycoprotein inhibitor GF-120918 662 
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(elacridar) is presented as the mean + S.D. (n=3). Marker drugs include a transcellular marker 663 
(metoprolol), a paracellular marker (atenolol) and a P-gp substrate (indinavir). 664 
 665 
  666 
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Table 1: Physicochemical properties of the heterocycles 792 
Compound MW (g/mol) HBd Hba RB LogD (7.4) PSA (Å²) pKa Kliver:blood 
Drug likea < 500 ≤ 5 ≤ 5 ≤ 10 ≤ 5 ≤ 140 
 
 
1271 270 1 2 4 2.8 55 10.02 7.74 
1210 209 3 3 1 2.0 50 11.64 24.83 
1270 300 1 2 5 3.6 42 13.49 17.11 
1269 333 2 2 5 4.3 58 11.52/13.61 12.24 
1214 319 2 2 4 4.3 58 10.59/11.63 10.33 
1396 225 1 1 1 3.7 26 / 25.68 
1365 330 1 2 4 4.8 42 10.87 7.32 
1350 330 1 2 4 5.2 42 10.70 7.25 
1352 334 1 2 4 4.8 55 10.01 7.43 
1213 320 1 2 4 4.4 55 10.33 6.99 
1354 366 1 3 4 5.0 51 10.49 9.14 
1367 350 1 2 4 5.7 42 10.05 8.06 
1398 319 1 1 4 4.7 42 10.60 7.67 
1349 338 1 2 5 5.1 42 13.48 16.73 
1399 335 1 1 4 5.5 29 10.74 7.39 
1211 286 1 2 4 3.7 42 10.50 10.63 
1348 350 1 2 4 5.7 42 10.49 8.74 
a (Lipinski et al., 2001) 793 
Abbreviations: MW molecular weight; HBd hydrogen bond donor; HBa hydrogen bond acceptor; RB 794 
rotatable bond; LogD distribution-coefficient; PSA polar surface area; pKa acid dissociation constant; 795 
Kliver:blood liver-to-blood partition coefficient. 796 
  797 
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Table 2 Km and Km corrected for the unbound fraction in hepatocytes or microsomes for the 798 
metabolism of compound 1210 in rat liver microsomes and suspended rat hepatocytes along with 799 
calculated Kpu,u in suspended rat hepatocytes. 800 
  Model system 
  Rat liver microsoms Suspended rat hepatocytes 
Km (μM) 38.33 7.80 
Km x fu (μM) 33.73 7.02 
Kpu,u   4.77 
Abbreviations: RLM rat liver microsomes; SRH suspended rat hepatocytes; Km Michaelis Menten 801 
constant; fu unbound fraction; Kpu,u ratio of the intracellular to extracellular unbound concentration. 802 
 803 
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Table 3 In vivo prediction for hepatic clearance and extraction ratio (ER). 805 
 Compound ClH,met ClH,uptake ClH ER Class 
 (ml/min/kg 
bodyweight) 
(ml/min/kg 
bodyweight) 
(ml/min/kg 
bodyweight) 
  
1271 4.6 18.0 5.4 0.19 P 
1210 23.0 26.4 23.1 0.82 E 
1270 12.6 23.8 12.0 0.42 I 
1269 4.1 22.6 4.7 0.16 P 
1214 17.3 25.6 16.0 0.56 I 
1396 8.4 18.9 13.8 0.49 I 
1365 3.0 6.1 2.1 0.08 P 
1350 0.2 7.0 0.3 0.01 P 
1352 1.2 4.2 1.6 0.06 P 
1213 1.7 20.3 2.7 0.10 P 
1354 0.3 5.0 0.5 0.02 P 
1367 1.5 2.2 1.1 0.04 P 
1398 0.8 11.2 0.8 0.03 P 
1349 4.7 23.2 5.8 0.21 P 
1399 0.6 15.6 0.9 0.03 P 
1211 0.2 8.8 0.2 0.01 P 
1348 0.5 7.8 0.6 0.02 P 
Abbreviations: ClH,met predicted in vivo clearance based on metabolism; ClH,uptake predicted in vivo 806 
clearance based on uptake; ClH predicted in vivo clearance based on uptake and metabolism; ER 807 
extraction ratio; P poor clearance; I intermediate clearance; E extensive clearance. 808 
 809 
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Table 4 Classification of the heterocycles in the BCS and BDDCS 811 
Compound Solubility Permeability  BCS Class Metabolism BDDCS Class 
   Class   (ER)   
1271 I H I/II P III/IV 
1210 H H I E I 
1270 P H II I II/IV 
1269 P H II P IV 
1214 P H II I II/IV 
1396 I H I/II I I-IV 
1365 P H II P IV 
1350 P H II P IV 
1352 P H II P IV 
1213 P H II P IV 
1354 P H II P IV 
1367 P H II P IV 
1398 P H II P IV 
1349 P I II/IV P IV 
1399 P I II/IV P IV 
1211 P I II/IV P IV 
1348 P I II/IV P IV 
Solubility based on threshold values: high solubility (H) > 500 mg/250 ml, intermediate solubility (I) 812 
10 mg/250ml < x < 500 mg/250ml or poor solubility (P) < 10 mg/250 ml 813 
Abbreviations: BCS biopharmaceutics classification system; BDDCS biopharmaceutics drug disposition 814 
classification system; USP United States Pharmacopeia. PI practically insoluble, VSS very slightly 815 
soluble, SS, slightly soluble 816 
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